Zortix
Sign in
What the podcasts are saying about
LLY
In-depth coverage
15
Mentions · 7d
30
Mentions · 30d
30
Mentions · 90d
26
Episodes
Latest attributed ideas · most recent first
18 JULTHOUGHTFUL MONEY · 05:10
Rotation from semiconductors to defensive growth
“The guest argued that capital is rotating out of highly leveraged semiconductor stocks and into defensive growth and value sectors like healthcare, energy, and mega-cap tech.”
In depth · 4/5Verify in source →
18 JULTHE ALPHA EXCHANGE · 10:30
AI-driven drug discovery boom
“The convergence of AI, advanced computing, and biotechnology is set to radically accelerate drug discovery and disrupt global healthcare expenditures.”
Substantive discussion · 3/5Verify in source →
17 JULTHE COMPOUND AND FRIENDS · 08:30
Lobbying intensity is a quantifiable investment factor
“The guest argued that measuring a company's lobbying spend relative to its size is a powerful, quantifiable factor for predicting stock outperformance.”
Core thesis · 5/5Verify in source →
17 JULTHE COMPOUND AND FRIENDS · 07:30
Late-cycle rotation favors energy and defensive sectors
“The discussion highlighted a classic late-cycle market rotation away from high-beta technology leaders toward energy, materials, and consumer defensive sectors.”
Substantive discussion · 3/5Verify in source →
17 JULTHE COMPOUND AND FRIENDS · 07:10
Private collective action protects corporate interests
“The guest argued that the most effective way for corporate leaders to counter political pressure from the Trump administration is through private, collective industry action rather than public grandstanding or individual compliance.”
In depth · 4/5Verify in source →
17 JULFORWARD GUIDANCE · 00:01
Agentic AI era triggers massive compute demand
“The transition from chatbot AI to agentic AI has increased compute requirements by a thousand times, expanding the investable universe beyond Nvidia.”
In depth · 4/5Verify in source →
17 JULA16Z PODCAST · 08:50
Peptide therapeutics will radically extend human longevity
“The guest argued that the discovery and production of upstream-regulating peptides will experience an AI-driven boom, leading to major breakthroughs in human healthspan and longevity.”
In depth · 4/5Verify in source →
17 JULA16Z PODCAST · 00:00
Direct-to-consumer peptide businesses face scaling limits
“The guest argued that direct-to-consumer peptide businesses are difficult to scale because they rely on placebo effects and lack demonstrable clinical value compared to established pharmaceutical giants.”
Substantive discussion · 3/5Verify in source →
17 JULA16Z PODCAST · 10:15
Eli Lilly faces a long-term GLP-1 patent cliff
“The long-term valuation of Eli Lilly is threatened by the inevitable transition of GLP-1 weight-loss drugs to cheap generics.”
Substantive discussion · 3/5Verify in source →
17 JULWSJ WHAT'S NEWS · 04:15
Medicare weight loss drug pilot begins
“A major expansion of Medicare coverage will offer select weight loss drugs for a $50 monthly co-pay, potentially benefiting up to 20 million eligible seniors.”
Substantive discussion · 3/5Verify in source →
17 JULTHE POMP PODCAST · 01:30
Broadening market rally beyond AI hyperscalers
“The market thesis argues that the S&P 500 will see a broadening of performance into healthcare, insurance, and banking, while hyperscalers experience multiple compression and flat performance.”
Substantive discussion · 3/5Verify in source →
16 JULTHE POMP PODCAST · 10:45
Eli Lilly as a sovereign AI leader
“The guest argued that Eli Lilly remains a high-conviction compounder due to its early adoption of sovereign AI infrastructure to accelerate drug discovery.”
Substantive discussion · 3/5Verify in source →
16 JULTHE ACQUIRERS PODCAST · 09:10
GLP-1s as a structural healthcare disruptor
“The GLP-1 drug class represents a structural shift in global healthcare due to its wide-ranging metabolic, cardiovascular, and potential cognitive benefits.”
Substantive discussion · 3/5Verify in source →
16 JULALL-IN WITH CHAMATH, JASON, SACKS & FRIEDBERG · 08:40
GLP-1 price drops to drive massive savings
“The guest argued that lowering the price of GLP-1 drugs to $150-$200 will dramatically reduce chronic illness rates and return money to the American taxpayer within two years.”
Core thesis · 5/5Verify in source →
16 JULWSJ WHAT'S NEWS · 06:55
Novo Nordisk leads Eli Lilly in weight-loss pills
“Novo Nordisk's Wegovy pill is capturing the majority of the early GLP-1 oral market share over Eli Lilly's competing offering.”
Substantive discussion · 3/5Verify in source →
4 JULA16Z PODCAST · 10:15
Innovative control arms slash trial costs
“The guest argued that the adoption of innovative control arms in clinical trials allows drug developers to bypass expensive placebo groups by utilizing historical control data.”
Substantive discussion · 3/5Verify in source →
4 JULALL-IN WITH CHAMATH, JASON, SACKS & FRIEDBERG · 07:15
Retatrutide positions Lilly for premium dominance
“Eli Lilly's upcoming triple-agonist peptide Retatrutide is framed as a premium 'upgrade' product that will command high margins by targeting fat loss while preserving muscle.”
Core thesis · 5/5Verify in source →
4 JULODD LOTS · 08:30
GLP-1 manufacturing expansion drives regional supply chains
“Eli Lilly's $3.5 billion GLP-1 manufacturing investment in Pennsylvania is expected to catalyze localized supply chain opportunities and regional employment.”
Substantive discussion · 3/5Verify in source →
4 JULTHOUGHTFUL MONEY · 08:30
Impending rotation from tech to defensive sectors
“Extreme overbought conditions in technology and momentum factors suggest an imminent rotation into defensive, low-beta, and value-oriented sectors.”
In depth · 4/5Verify in source →
4 JULTHE POMP PODCAST · 00:50
Eli Lilly scales longevity via AI drug discovery
“The bull case for Eli Lilly centers on its use of AI and strategic acquisitions to lower treatment costs, triggering Jevons paradox to exponentially expand its addressable market in longevity and chronic disease.”
In depth · 4/5Verify in source →
4 JULTHE POMP PODCAST · 12:15
Eli Lilly is an AI play in disguise
“The bull case for Eli Lilly is that it is leveraging AI partnerships and acquisitions to accelerate drug discovery and monetize stalled biotech IP, transforming it into a tech-like growth compounder.”
In depth · 4/5Verify in source →
4 JULTHE POMP PODCAST · 01:50
Eli Lilly's specialized AI model dominance
“The speakers argued that Eli Lilly is positioned to become a leading AI company by leveraging its proprietary clinical data and dedicated GPU infrastructure to build specialized models rather than relying on generalist LLMs.”
Core thesis · 5/5Verify in source →
4 JULTHE POMP PODCAST · 00:45
Peptides represent software for human biology
“The guest argued that peptides act as biological software, marking a structural market rotation from tech hardware to biotech application layers.”
Core thesis · 5/5Verify in source →
4 JULTHE POMP PODCAST · 04:15
AI innovation shifts to physical hardware bottlenecks
“The speaker argued that venture capital and top-tier talent are shifting toward physical hardware and AI-driven manufacturing to resolve real-world supply and production bottlenecks.”
Substantive discussion · 3/5Verify in source →
4 JULTHE BLOOMBERG SURVEILLANCE · 05:40
AI value shifts to application layer
“The bullish case for AI applications argues that the most powerful investment opportunities are moving toward companies leveraging proprietary data.”
Substantive discussion · 3/5Verify in source →
4 JULTHE MEB FABER SHOW · 06:10
Market leadership inevitably shifts over decades
“The discussion highlighted that capitalism's creative destruction ensures that market-leading industries and companies completely change over multi-decade periods.”
Explored · 3/5Verify in source →
4 JULWSJ WHAT'S NEWS · 05:05
Agentic AI transforms corporate operational efficiency
“Agentic AI is driving rapid efficiency gains across core corporate functions like coding, customer service, and DevOps, fundamentally changing internal operations for major enterprises.”
In depth · 4/5Verify in source →
4 JULFORWARD GUIDANCE · 05:15
Higher rates drive real-world innovation boom
“The discussion outlined how the transition to a higher interest rate environment is correcting the capital misallocations of the 2010s, shifting investment from financial engineering back to productive, real-world innovation.”
Substantive discussion · 3/5Verify in source →
4 JULCNBC FAST MONEY · 01:15
Patent cliffs trigger biotech M&A wave
“Large pharmaceutical companies are expected to acquire small-to-mid-cap biotech firms to replace an estimated $275 billion in revenue threatened by upcoming patent expirations.”
In depth · 4/5Verify in source →
4 JULCNBC FAST MONEY · 09:40
M&A and clinical catalysts revive biotech
“The biotech sector is experiencing a significant rally driven by major M&A activity, corporate investments, and upcoming clinical trial data.”
Substantive discussion · 3/5Verify in source →
The weekly signal

Get a weekly digest of what podcasts said about your watchlist.

Pick a few tickers. Once a week we send the most-discussed ideas across finance podcasts — attributed, with a link to verify. No noise, no advice.

Double opt-in: we’ll email you to confirm before anything else. We store your email and chosen tickers only to send this digest — nothing else, never shared.

Related tickers
NVDAMSFTGOOGLAMZNMETAAAPLMSTRSPYMUTSLACRMCOIN
Browse all tickers →This week’s signal →
MENTIONS & DEPTH REFLECT PODCAST DISCUSSION VOLUME · NOT A RATING, FORECAST, OR RECOMMENDATION